NCT03407521

Brief Summary

the investigators aimed to study the efficacy and safety of nitric oxide donors when combined with prostaglandins in induction of second trimester abortion expecting that both drugs when used together will be of greater efficiency and associated with less side effects. the study included 60 women with gestational age between 13weeks+0day and 26weeks+6days indicated for pregnancy termination due to maternal or fetal cause.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Apr 2017

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 12, 2017

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 22, 2017

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 15, 2017

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

January 16, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

January 23, 2018

Completed
Last Updated

February 28, 2018

Status Verified

February 1, 2018

Enrollment Period

6 months

First QC Date

January 16, 2018

Last Update Submit

February 26, 2018

Conditions

Keywords

second trimester abortion

Outcome Measures

Primary Outcomes (1)

  • induction abortion interval

    time needed to induce abortion in second trimester abortion

    24 hours

Study Arms (2)

study group

ACTIVE COMPARATOR

misoprostol tab 200mcg 2 tab at first then one every 4 hours with isosorbide mononitrate 20mg once

Drug: MisoprostolDrug: isosorbide mononitrate

control group

PLACEBO COMPARATOR

misoprostol tab 200mcg 2 tab at first then one every 4 hours with placebo

Drug: MisoprostolDrug: Placebo

Interventions

induction of abortion using misoprostol

control groupstudy group

isosorbide mononitrate

study group

Placebo

control group

Eligibility Criteria

Age16 Years - 40 Years
Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Age 16 -40 years
  • Missed abortion
  • Singelton pregnancy
  • Gestationl age between 13 and 26 weeks of pregnancy
  • Normal uterus and cevix on clinical examination
  • Cervix is not dilatated
  • No uterine activity and vaginal bleeding
  • Written and informed consent by the patient
  • Unscarred uterus

You may not qualify if:

  • Presence of uterine contraction or bleeding
  • Evidences suggesting of onset of spontaneous abortion as Previous trial to induce abortion
  • Multifetal pregnancy
  • Suspicion of septic abortion
  • History of cervical surgery or manipulation
  • Uterine anomaly
  • IUD in situ
  • Associtaed hemorrhagic disorder
  • History of adverse effects to vaginally adminstered medication
  • Inability to insert vaginal medication high in vagina

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Medicine Ain Shams University

Cairo, 11566, Egypt

Location

Related Publications (1)

  • Jain JK, Mishell DR Jr. A comparison of misoprostol with and without laminaria tents for induction of second-trimester abortion. Am J Obstet Gynecol. 1996 Jul;175(1):173-7. doi: 10.1016/s0002-9378(96)70270-3.

MeSH Terms

Interventions

Misoprostolisosorbide-5-mononitrate

Intervention Hierarchy (Ancestors)

Prostaglandins E, SyntheticProstaglandins, SyntheticProstaglandinsEicosanoidsFatty Acids, UnsaturatedFatty AcidsLipidsAutacoidsInflammation MediatorsBiological Factors

Study Officials

  • mohamed ab elsenity, MD

    Ain Shams University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer MD

Study Record Dates

First Submitted

January 16, 2018

First Posted

January 23, 2018

Study Start

April 12, 2017

Primary Completion

October 22, 2017

Study Completion

December 15, 2017

Last Updated

February 28, 2018

Record last verified: 2018-02

Data Sharing

IPD Sharing
Will not share

publish in scientific journals

Locations